ANTX (AN2 Therapeutics) Total Stockholders Equity: $75.92 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANTX AN2 Therapeutics Inc ANTX
22 GF Score
Price $5.51
! 4 Warning Signs
View Full Analysis

What is AN2 Therapeutics Total Stockholders Equity?

AN2 Therapeutics ANTX -0.72% 22 Total Stockholders Equity is $75.92 Mil as of Jun. 2026. GuruFocus rates ANTX with a GF Score™ of 22/100. The stock has 4 warning signs investors should review.

AN2 Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $75.92 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. AN2 Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was $2.09. The ratio of a company's debt over equity can be used to measure how leveraged this company is. AN2 Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.


AN2 Therapeutics  (NAS:ANTX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

AN2 Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

AN2 Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AN2 Therapeutics Total Stockholders Equity Related Terms


AN2 Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for AN2 Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AN2 Therapeutics Total Stockholders Equity Chart

AN2 Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 61.91 95.37 124.70 81.85 53.06

AN2 Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.84 60.38 53.06 81.76 75.92
ANTX
22GF Score
AN2 Therapeutics Inc ANTX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $75.92 Mil mean?
AN2 Therapeutics (ANTX) has a Total Stockholders Equity of $75.92 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for AN2 Therapeutics and its competitors.
Is AN2 Therapeutics' Total Stockholders Equity too high?
AN2 Therapeutics' current Total Stockholders Equity is $75.92 Mil. Overall, AN2 Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does AN2 Therapeutics' Total Stockholders Equity compare to ABOS and CRBP?
AN2 Therapeutics' Total Stockholders Equity of $75.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for AN2 Therapeutics and its competitors. AN2 Therapeutics's current Total Stockholders Equity is $75.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AN2 Therapeutics stock overvalued right now?
AN2 Therapeutics (ANTX) has a current Total Stockholders Equity of $75.92 Mil. The current Total Stockholders Equity is $75.92 Mil. AN2 Therapeutics' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For AN2 Therapeutics (ANTX), the current Total Stockholders Equity is $75.92 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AN2 Therapeutics Business Description

Address 1300 El Camino Real, Suite 100, Menlo Park, CA, USA, 94025
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
22GF Score

Get the complete analysis for ANTX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.51
Price